Home LiteratureArticle Details
PMID: 18047745 Published · epublish English Journal Article Review

Role of the ubiquitin system and tumor viruses in AIDS-related cancer.

BMC biochemistry ·Vol. 8 Suppl 1 ·2007-11-22 ·Pages S8

Shackelford J, Pagano JS

Abstract

Tumor viruses are linked to approximately 20% of human malignancies worldwide. This review focuses on examples of human oncogenic viruses that manipulate the ubiquitin system in a subset of viral malignancies; those associated with AIDS. The viruses include Kaposi's sarcoma herpesvirus, Epstein-Barr virus and human papilloma virus, which are causally linked to Kaposi's sarcoma, certain B-cell lymphomas and cervical cancer, respectively. We discuss the molecular mechanisms by which these viruses subvert the ubiquitin system and potential viral targets for anti-cancer therapy from the perspective of this system. Publication history: Republished from Current BioData's Targeted Proteins database (TPdb; http://www.targetedproteinsdb.com).

MeSH Terms
Acquired Immunodeficiency Syndrome/drug therapy,enzymology,virology Animals Antineoplastic Agents/administration & dosage Humans Neoplasms/drug therapy,enzymology,virology Oncogenic Viruses/drug effects,physiology Tumor Virus Infections/drug therapy,enzymology,virology Ubiquitin/physiology
Chemicals
Antineoplastic Agents Ubiquitin
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Shackelford Julia
Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7295, USA. shackelfordj@yahoo.com
Pagano Joseph S
References (118)
118 references, click to expand
  1. Papillomaviruses as targets for cancer gene therapy.
    Cancer Gene Ther. 2006 May;13(5):445-50 PMID: 16341140
  2. Spectrum of AIDS-associated malignant disorders.
    Lancet. 1998 Jun 20;351(9119):1833-9 PMID: 9652666
  3. Immunologic aspects of protein degradation by the ubiquitin-proteasome system.
    Isr Med Assoc J. 2004 Jul;6(7):420-4 PMID: 15274534
  4. Kaposi's sarcoma-associated herpesvirus (KSHV/HHV8): key aspects of epidemiology and pathogenesis.
    AIDS Rev. 2003 Oct-Dec;5(4):222-9 PMID: 15012001
  5. Prostratin and bortezomib are novel inducers of latent Kaposi's sarcoma-associated herpesvirus.
    Antivir Ther. 2005;10(6):745-51 PMID: 16218174
  6. The role of human papillomavirus oncoproteins E6 and E7 in apoptosis.
    Cancer Lett. 2002 Dec 15;188(1-2):15-24 PMID: 12406543
  7. [Epstein-Barr virus (EBV)-associated lymphomas and lymphoproliferative disorders].
    Nihon Rinsho. 2006 Mar;64 Suppl 3:635-8 PMID: 16615550
  8. Epstein-Barr virus oncogenesis and the ubiquitin-proteasome system.
    Oncogene. 2004 Mar 15;23(11):2107-15 PMID: 15021898
  9. Mechanisms of expression of HHV8, EBV and HPV in selected HIV-associated oral lesions.
    Oral Dis. 2002;8 Suppl 2:161-8 PMID: 12164651
  10. Treatments of AIDS-related Kaposi's sarcoma.
    Crit Rev Oncol Hematol. 2005 Mar;53(3):253-65 PMID: 15718150
  11. Natural products inhibiting the ubiquitin-proteasome proteolytic pathway, a target for drug development.
    Curr Med Chem. 2006;13(7):745-54 PMID: 16611064
  12. Latent membrane protein 2A of Epstein-Barr virus binds WW domain E3 protein-ubiquitin ligases that ubiquitinate B-cell tyrosine kinases.
    Mol Cell Biol. 2000 Nov;20(22):8526-35 PMID: 11046148
  13. Lysine-63-linked ubiquitination is required for endolysosomal degradation of class I molecules.
    EMBO J. 2006 Apr 19;25(8):1635-45 PMID: 16601694
  14. Proteasome inhibition in the treatment of cancer.
    Cell Cycle. 2005 Feb;4(2):290-6 PMID: 15655370
  15. Inhibition of Bak-induced apoptosis by HPV-18 E6.
    Oncogene. 1998 Dec 10;17(23):2943-54 PMID: 9881696
  16. Kaposi's sarcoma in the era of HAART-an update on mechanisms, diagnostics and treatment.
    AIDS Rev. 2005 Jan-Mar;7(1):56-61 PMID: 15875661
  17. Epstein-Barr virus activates beta-catenin in type III latently infected B lymphocyte lines: association with deubiquitinating enzymes.
    Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15572-6 PMID: 14663138
  18. Epstein-Barr virus (EBV) and its associated human cancers--genetics, epigenetics, pathobiology and novel therapeutics.
    Front Biosci. 2006 Sep 01;11:2672-713 PMID: 16720343
  19. Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis.
    Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8051-6 PMID: 10859362
  20. Biology of HPV in HIV infection.
    Adv Dent Res. 2006 Apr 01;19(1):99-105 PMID: 16672559
  21. Animal models for AIDS pathogenesis.
    Adv Pharmacol. 2000;49:479-514 PMID: 11013772
  22. A murine gammaherpesvirus.
    Acta Virol. 2000 Jun-Aug;44(3):211-26 PMID: 11155368
  23. Human papillomavirus type 16 E5 protein as a therapeutic target.
    Yonsei Med J. 2006 Feb 28;47(1):1-14 PMID: 16502480
  24. Proteasome inhibition in multiple myeloma: therapeutic implication.
    Annu Rev Pharmacol Toxicol. 2005;45:465-76 PMID: 15822185
  25. Tumor viruses and cell signaling pathways: deubiquitination versus ubiquitination.
    Mol Cell Biol. 2004 Jun;24(12):5089-93 PMID: 15169876
  26. HPV-related neoplasias in HIV-infected individuals.
    Eur J Cancer. 2001 Jul;37(10):1227-35 PMID: 11423255
  27. The proteasome: a new target for novel drug therapies.
    Am J Clin Pathol. 2001 Nov;116(5):637-46 PMID: 11710679
  28. The epidemiology of acquired immunodeficiency syndrome malignancies.
    Semin Oncol. 2000 Aug;27(4):390-401 PMID: 10950365
  29. Neoplastic conditions in the context of HIV-1 infection.
    Curr HIV Res. 2004 Oct;2(4):343-9 PMID: 15544455
  30. Human papillomavirus immortalization and transformation functions.
    Virus Res. 2002 Nov;89(2):213-28 PMID: 12445661
  31. Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase.
    Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18562-6 PMID: 16352731
  32. Immune response in cervical dysplasia induced by human papillomavirus: the influence of human immunodeficiency virus-1 co-infection -- review.
    Mem Inst Oswaldo Cruz. 2005 Feb;100(1):1-12 PMID: 15867955
  33. EBV latent membrane protein 1 up-regulates hypoxia-inducible factor 1alpha through Siah1-mediated down-regulation of prolyl hydroxylases 1 and 3 in nasopharyngeal epithelial cells.
    Cancer Res. 2006 Oct 15;66(20):9870-7 PMID: 17047048
  34. Strategies for human papillomavirus therapeutic vaccines and other therapies based on the E6 and E7 oncogenes.
    Ann N Y Acad Sci. 2005 Nov;1056:328-43 PMID: 16387699
  35. Infectious agents and cancer: criteria for a causal relation.
    Semin Cancer Biol. 2004 Dec;14(6):453-71 PMID: 15489139
  36. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.
    MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 PMID: 1361652
  37. Ubiquitination on nonlysine residues by a viral E3 ubiquitin ligase.
    Science. 2005 Jul 1;309(5731):127-30 PMID: 15994556
  38. [A new therapy with bortezomib, an oncologic medicinal product of the year 2004].
    Ann Pharm Fr. 2005 Sep;63(5):343-9 PMID: 16385784
  39. Interferon regulatory factor 7 is activated by a viral oncoprotein through RIP-dependent ubiquitination.
    Mol Cell Biol. 2007 Apr;27(8):2910-8 PMID: 17296724
  40. The ubiquitin/proteasome system in Epstein-Barr virus latency and associated malignancies.
    Semin Cancer Biol. 2003 Feb;13(1):69-76 PMID: 12507558
  41. Pathologic aspects of AIDS malignancies.
    Oncogene. 2003 Sep 29;22(42):6639-45 PMID: 14528289
  42. Pathogenesis of Kaposi's sarcoma.
    Hematol Oncol Clin North Am. 2003 Jun;17(3):717-45 PMID: 12852653
  43. Ubiquitin-mediated proteolysis: biological regulation via destruction.
    Bioessays. 2000 May;22(5):442-51 PMID: 10797484
  44. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product.
    EMBO J. 1989 Dec 20;8(13):4099-105 PMID: 2556261
  45. Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells.
    Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1218-23 PMID: 11158620
  46. Siah: new players in the cellular response to hypoxia.
    Cell Cycle. 2004 Nov;3(11):1345-7 PMID: 15492505
  47. Cellular targets of the oncoproteins encoded by the cancer associated human papillomaviruses.
    Princess Takamatsu Symp. 1991;22:239-48 PMID: 1668886
  48. Leukemia-lymphoma cell lines as model systems for hematopoietic research.
    Ann Med. 2003;35(6):404-12 PMID: 14572164
  49. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53.
    FEBS Lett. 1997 Dec 22;420(1):25-7 PMID: 9450543
  50. Human herpesvirus 8: biology and role in the pathogenesis of Kaposi's sarcoma and other AIDS-related malignancies.
    Curr HIV/AIDS Rep. 2004 Apr;1(1):5-11 PMID: 16091217
  51. Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV-containing cervical tumor cells.
    Oncogene. 2001 Aug 2;20(34):4740-9 PMID: 11498796
  52. Proteasome inhibitors: from research tools to drug candidates.
    Chem Biol. 2001 Aug;8(8):739-58 PMID: 11514224
  53. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis.
    J Natl Cancer Inst. 2000 May 3;92(9):690-8 PMID: 10793105
  54. Classification of papillomaviruses.
    Virology. 2004 Jun 20;324(1):17-27 PMID: 15183049
  55. Cell transformation by the E7 oncoprotein of human papillomavirus type 16: interactions with nuclear and cytoplasmic target proteins.
    Adv Cancer Res. 2000;78:1-29 PMID: 10547667
  56. EBV-associated B- and T-cell posttransplant lymphoproliferative disorders following primary EBV infection in a kidney transplant recipient.
    Am J Clin Pathol. 2005 Feb;123(2):222-8 PMID: 15842046
  57. Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome system.
    Semin Cancer Biol. 2003 Feb;13(1):59-67 PMID: 12507557
  58. The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells.
    J Biol Chem. 1998 Mar 13;273(11):6439-45 PMID: 9497376
  59. Epstein-Barr virus induces invasion and metastasis factors.
    Anticancer Res. 2003 May-Jun;23(3A):2133-8 PMID: 12894587
  60. Proteasome: an emerging target for cancer therapy.
    Anticancer Drugs. 2005 Jun;16(5):475-81 PMID: 15846112
  61. Inhibition of lysosome and proteasome function enhances human immunodeficiency virus type 1 infection.
    J Virol. 2005 May;79(9):5705-12 PMID: 15827185
  62. The role of TP53 in Cervical carcinogenesis.
    Hum Mutat. 2003 Mar;21(3):307-12 PMID: 12619117
  63. Virally targeted therapies for EBV-associated malignancies.
    Oncogene. 2003 Aug 11;22(33):5122-30 PMID: 12910249
  64. The role of the E6-p53 interaction in the molecular pathogenesis of HPV.
    Oncogene. 1999 Dec 13;18(53):7690-700 PMID: 10618709
  65. Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2.
    Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13057-62 PMID: 11087859
  66. Epstein-Barr virus: 40 years on.
    Nat Rev Cancer. 2004 Oct;4(10):757-68 PMID: 15510157
  67. NF-kappaB in human disease: current inhibitors and prospects for de novo structure based design of inhibitors.
    Curr Med Chem. 2005;12(3):357-74 PMID: 15723624
  68. [The HIV nef and the Kaposi-sarcoma-associated virus K3/K5 proteins: "parasites"of the endocytosis pathway].
    Med Sci (Paris). 2003 Jan;19(1):100-6 PMID: 12836198
  69. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product.
    Science. 1989 Feb 17;243(4893):934-7 PMID: 2537532
  70. HIV update 2005: origins, issues, prospects, and complications.
    Cleve Clin J Med. 2005 Jan;72(1):73-8 PMID: 15691060
  71. A novel class of herpesvirus-encoded membrane-bound E3 ubiquitin ligases regulates endocytosis of proteins involved in immune recognition.
    J Cell Biol. 2001 Dec 24;155(7):1265-73 PMID: 11756476
  72. Gene therapy for the treatment of AIDS: animal models and human clinical experience.
    Front Biosci. 1999 May 15;4:D468-75 PMID: 10331991
  73. Vaccines against human papillomavirus and cervical cancer: promises and challenges.
    Oncologist. 2005 Aug;10(7):528-38 PMID: 16079320
  74. Up-regulation of beta-catenin by a viral oncogene correlates with inhibition of the seven in absentia homolog 1 in B lymphoma cells.
    Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18431-6 PMID: 16344472
  75. AIDS-associated malignancies.
    Cancer Chemother Biol Response Modif. 2003;21:717-46 PMID: 15338771
  76. Viruses as potential targets for therapy in HIV-associated malignancies.
    Hematol Oncol Clin North Am. 2003 Jun;17(3):697-702, v-vi PMID: 12852651
  77. The Epstein-Barr virus latent membrane protein 2A PY motif recruits WW domain-containing ubiquitin-protein ligases.
    Virology. 2000 Mar 1;268(1):178-91 PMID: 10683340
  78. A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy.
    Lancet. 2006 May 6;367(9521):1495-502 PMID: 16679162
  79. Bortezomib: proteasome inhibition as an effective anticancer therapy.
    Annu Rev Med. 2006;57:33-47 PMID: 16409135
  80. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.
    Cell. 1990 Dec 21;63(6):1129-36 PMID: 2175676
  81. Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins.
    Carcinogenesis. 2003 Feb;24(2):159-69 PMID: 12584163
  82. Initiation of the host response against murine gammaherpesvirus infection in immunocompetent mice.
    Viral Immunol. 2004;17(4):473-80 PMID: 15671745
  83. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation.
    Crit Rev Oncol Hematol. 2005 Oct;56(1):155-67 PMID: 15979320
  84. Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus.
    Nature. 1998 Aug 6;394(6693):588-92 PMID: 9707121
  85. Cancer incidence trends in women at high risk of human immunodeficiency virus (HIV) infection.
    Int J Cancer. 1993 Sep 9;55(2):208-12 PMID: 8370617
  86. Ubiquitylation of MHC class I by the K3 viral protein signals internalization and TSG101-dependent degradation.
    EMBO J. 2002 May 15;21(10):2418-29 PMID: 12006494
  87. Targeting of host-cell ubiquitin pathways by viruses.
    Essays Biochem. 2005;41:139-56 PMID: 16250903
  88. The human papillomavirus E7 oncoprotein functionally interacts with the S4 subunit of the 26 S proteasome.
    J Biol Chem. 1997 Nov 28;272(48):30135-40 PMID: 9374493
  89. Epstein-Barr virus in the pathogenesis of NPC.
    Semin Cancer Biol. 2002 Dec;12(6):431-41 PMID: 12450729
  90. AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy.
    Curr Opin Infect Dis. 2006 Feb;19(1):14-9 PMID: 16374212
  91. Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7.
    J Virol. 2001 Aug;75(16):7583-91 PMID: 11462030
  92. Epstein-Barr virus LMP2A: regulating cellular ubiquitination processes for maintenance of viral latency?
    Trends Immunol. 2004 Aug;25(8):422-6 PMID: 15275641
  93. The SCID-hu mouse: an in vivo model for HIV-1 infection in humans.
    Mol Med Today. 1997 Jun;3(6):246-53 PMID: 9211415
  94. Mechanism of HPV E6 proteins in cellular transformation.
    Semin Cancer Biol. 1996 Dec;7(6):317-26 PMID: 9284524
  95. Functional organization of MIR2, a novel viral regulator of selective endocytosis.
    J Biol Chem. 2002 Feb 22;277(8):6124-30 PMID: 11751860
  96. Not just research tools--proteasome inhibitors offer therapeutic promise.
    Nat Med. 2002 Apr;8(4):338-40 PMID: 11927937
  97. Epstein-Barr virus infections: prospects for treatment.
    J Antimicrob Chemother. 2005 Aug;56(2):277-81 PMID: 16006448
  98. Epstein-Barr virus-associated carcinomas: facts and fiction.
    J Pathol. 2003 Feb;199(2):140-5 PMID: 12533825
  99. AIDS malignancies in the era of highly active antiretroviral therapy.
    Oncology (Williston Park). 2002 May;16(5):657-65; discussion 665, 668-70 PMID: 12108891
  100. Systemic treatment of AIDS-related Kaposi sarcoma: current status and perspectives.
    Cancer Treat Rev. 2006 Oct;32(6):445-55 PMID: 16860939
  101. Proteasome inhibition as a novel therapeutic target in human cancer.
    J Clin Oncol. 2005 Jan 20;23(3):630-9 PMID: 15659509
  102. The KSHV immediate-early transcription factor RTA encodes ubiquitin E3 ligase activity that targets IRF7 for proteosome-mediated degradation.
    Immunity. 2005 Jan;22(1):59-70 PMID: 15664159
  103. Targeting the proteasome as a therapeutic strategy against haematological malignancies.
    Expert Opin Investig Drugs. 2006 Feb;15(2):117-30 PMID: 16433592
  104. Modeling AIDS in a mouse.
    Hosp Pract (1995). 1996 Sep 15;31(9):41-8, 53-5, 59-60 PMID: 8814120
  105. Emerging human papillomavirus vaccines.
    Expert Opin Emerg Drugs. 2005 Feb;10(1):5-19 PMID: 15757400
  106. Avoiding proteasomal processing: the case of EBNA1.
    Curr Top Microbiol Immunol. 2002;269:23-36 PMID: 12224511
  107. Lymphoma and the control of B cell growth and differentiation.
    Curr Mol Med. 2006 May;6(3):291-308 PMID: 16712476
  108. Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis.
    Microbiol Mol Biol Rev. 2003 Jun;67(2):175-212, table of contents PMID: 12794189
  109. Transgenic animal models of human papillomavirus-dependent disease (Review).
    Int J Oncol. 2000 May;16(5):853-70 PMID: 10762621
  110. Proteasome function in antigen presentation: immunoproteasome complexes, Peptide production, and interactions with viral proteins.
    Curr Protein Pept Sci. 2004 Jun;5(3):153-61 PMID: 15180520
  111. Post-transplant lymphoproliferative disorders.
    Annu Rev Med. 2005;56:29-44 PMID: 15660500
  112. AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy.
    Oncologist. 2005 Jun-Jul;10(6):412-26 PMID: 15967835
  113. Human papillomavirus oncogenesis.
    Clin Lab Med. 2000 Jun;20(2):383-406 PMID: 10863646
  114. Human B-lymphoid cell lines.
    Hum Cell. 1992 Mar;5(1):25-41 PMID: 1329931
  115. Epstein-Barr virus and oncogenesis: from latent genes to tumours.
    Oncogene. 2003 Aug 11;22(33):5108-21 PMID: 12910248
  116. Murine gammaherpesvirus 68: a model for the study of gammaherpesvirus pathogenesis.
    Trends Microbiol. 1998 Jul;6(7):276-82 PMID: 9717216
  117. The interaction between p53 and papillomaviruses.
    Semin Cancer Biol. 1999 Dec;9(6):387-95 PMID: 10712885
  118. The proteasome: a suitable antineoplastic target.
    Nat Rev Cancer. 2004 May;4(5):349-60 PMID: 15122206
Article Info
Journal
BMC biochemistry
Abbr.
BMC Biochem
ISSN
1471-2091
DOI
10.1186/1471-2091-8-S1-S8
Email
shackelfordj@yahoo.com
Published
2007-11-22
Epub
2007-00-22
Pages
S8
Language
English
Region
England
NLM ID
101084098
PMCID
PMC2106372
Subset
IM
External Links
PubMed source DOI: 10.1186/1471-2091-8-S1-S8 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2